Obesity, diabetes, serum glucose, and risk of primary liver cancer by birth cohort, race/ethnicity, and sex: Multiphasic health checkup study by Petrick, Jessica L. et al.
Obesity, Diabetes, Serum Glucose, and Risk of Primary Liver 
Cancer by Birth Cohort, Race/Ethnicity, and Sex: Multiphasic 
Health Checkup Study
Jessica L. Petrick1,*, Neal D. Freedman1, Jane Demuth2, Baiyu Yang1, Stephen K. Van Den 
Eeden3, Lawrence S. Engel4, and Katherine A. McGlynn1
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
2Information Management Services Inc., Silver Spring, MD
3Division of Research, Kaiser Permanente Northern California, Oakland, CA
4Department of Epidemiology, University of North Carolina, Chapel Hill, NC
Abstract
Objective—Obesity and diabetes have been associated with liver cancer. However, recent US-
based studies have suggested a lack of association between obesity and liver cancer among blacks 
and women.
Methods—We conducted a nested case-control study within the Multiphasic Health Checkup 
(MHC) cohort of Kaiser Permanente Northern California (KPNC) members. Liver cancer was 
diagnosed using the KPNC Cancer Registry. Detailed self-administered questionnaires and a 
standardized examination that included measurement of height and weight and a 1-hour glucose 
tolerance test were completed prior to diagnosis of liver cancer for cases (n=450) and matched 
controls (4,489). Height and weight were utilized to calculate BMI (kg/m2) as a measure of 
adiposity: underweight (15–<18.5 kg/m2), normal weight (18.5–<25 kg/m2), overweight (25–<30 
kg/m2), and obese (≥30 kg/m2). Conditional logistic regression was used to estimate odds ratios 
(ORs) and 95% confidence intervals (CI) for the association between BMI, diabetes, and serum 
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glucose with subsequent incidence of liver cancer, in models that were stratified by birth cohort, 
race/ethnicity, and sex.
Results—Compared to normal weight individuals, obese individuals had a 2.4-fold increased risk 
of liver cancer (OR=2.38, 95% CI: 1.68–3.36), and overweight individuals had a 32% increased 
risk (OR=1.32, 95% CI: 1.03–1.70). This association did not differ when stratified by birth cohort, 
race/ethnicity, or sex (pint>0.05). Among blacks and women, obesity was associated with at least a 
2-fold increased risk of liver cancer (OR=2.29, 95% CI: 1.22–4.28 and OR=2.00, 95% CI: 1.14–
3.52, respectively). More moderate increased odds ratios were noted for diabetes (OR=1.28, 95% 
CI: 0.65–2.54) and serum glucose ≥200 mg/dL (OR=1.63, 95% CI: 0.48–5.55), although the 
results did not attain statistical significance.
Conclusion—In summary, our finding of a positive association between obesity and liver cancer 
suggests that a higher BMI may increase the risk of liver cancer in the US, for both sexes and all 
race/ethnicities.
1. INTRODUCTION
Liver cancer usually develops on a background of oxidative stress and inflammation, 
triggered by chronic infection with hepatitis B or C virus (HBV or HCV), excess alcohol 
consumption, aflatoxin exposure, or obesity [1]. Obesity can cause chronic, low-grade 
systemic inflammation through increased levels of TNF-α, IL-6, leptin, free fatty acids, and 
TLR4 and decreased adiponectin levels [2]. This systemic inflammation is believed to 
contribute to metabolic dysregulation, including onset of insulin resistance and subsequent 
diabetes [3], and the development and progression of nonalcoholic fatty liver disease 
(NAFLD) to non-alcoholic steatohepatitis, fibrosis, cirrhosis; culminating in liver cancer 
development [2]. Diabetes further contributes to metabolic dysregulation and may lead to the 
development and progression of NAFLD [4] and risk of liver cancer, independent of obesity 
[5–7].
The incidence of primary liver cancer, which includes both hepatocellular carcinoma and 
intrahepatic cholangiocarcinoma, has been increasing in the United States (US) since 1980 
[8], approximately ten years after the beginning of the obesity epidemic [9]. Although there 
is substantial evidence from prospective cohort studies that obesity is associated with 
increased risk of liver cancer [10], only two studies have investigated this association in a 
US population, where the risk factor profile may be different from other populations. Both 
cohort studies reported that obesity is associated with 64–94% increased risk of liver cancer, 
but the association may differ by race/ethnicity or sex. Additionally, both of these 
prospective studies were conducted after the start of the obesity epidemic in the US and 
therefore may have very different risk factor profiles [11](Campbell et al., Under Review). 
Diabetes has been consistently associated with a 2–2.5 fold increased risk of liver cancer 
[12–15], but few studies, all non-US, have investigated serum glucose measures [16, 17].
Thus, we examined the effects of adiposity on liver cancer risk by examining the association 
between obesity, diabetes, and serum glucose and subsequent risk of liver cancer in a 
racially and ethnically diverse US population of men and women, the majority of whom 
were recruited beginning in 1964 prior to the start of the obesity epidemic in the 1970s [9].
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2. METHODS
2.1. Study Design and Population
We conducted a nested case-control study, within a large cohort, of the associations between 
body mass index, diabetes, and glucose and the risk of primary liver cancer.
The Multiphasic Health Checkup (MHC) cohort consists of Kaiser Permanente Northern 
California (KPNC) members who underwent a MHC at either the Kaiser Oakland or San 
Francisco Medical Center. Kaiser Permanente members presenting for a routine health 
examination, for any reason, were invited to complete a detailed questionnaire and 
standardized physical examination, including clinical and laboratory testing [18, 19]. Kaiser 
Permanente members are broadly representative of the San Francisco Bay region underlying 
census demographics [20, 21]. The present study includes cohort members who completed 
an examination between 1964 and 1992, with the majority of individuals (69.9%) enrolled 
between 1964 and 1973.
2.2. Exposure Measurements
Height and weight were measured during a standardized physical examination by trained 
examiners, using a written, systematic protocol and standardized instruments. These 
measurements were utilized to calculate BMI (kg/m2) as a measure of adiposity and 
categorized according to the World Health Organization criteria [22]: underweight (<18.5 
kg/m2), normal weight (18.5–<25 kg/m2), overweight (25–<30 kg/m2), and obese (≥30 kg/
m2). Individuals with a BMI of less than 15 were excluded. MHC cohort participants 
additionally underwent a 1-hour glucose tolerance test to determine serum glucose levels 
(mg/dL; categorized as <140, 140–199, and ≥200). Finally, participants reported whether 
they had ever been diagnosed with diabetes or “sugar disease” – type was not specified.
2.3. Outcome Measurements
To determine cancer outcomes, the KPNC Cancer Registry was used. Prior to 1973, KPNC 
maintained a cancer registry for internal purposes. In 1973, the KPNC Cancer Registry was 
reorganized as part of the National Cancer Institute’s Surveillance, Epidemiology, and End 
Results programs in California. Incident primary liver cancer cases were defined according 
to the International Classification of Disease for Oncology diagnostic code of C22. We 
identified 450 cases of incident liver cancer occurring after the individual’s interview date 
through December 31, 2009 (mean follow-up = 22.5 years). The KPNC Cancer Registry has 
a follow-up rate of over 95% and a case ascertainment rate of over 98% [23].
To maximize power [24], ten controls were individually matched to each liver cancer case. 
However, for 25 cases, ten eligible controls could not be identified. Matching factors 
included period of enrollment in the MHC cohort (enrollment years 1964–1973, 1973–1977, 
1978–1985, or 1985–1992), age at enrollment (±1 year), date of (first, if two) blood draw 
(±6 months), sex, and race (White, Black, Asian, or Other). If the case had two blood draws, 
date of second blood draw (±12 months) was also included as a matching criterion. 
Matching on blood draw was conducted for a parent study, which examined the association 
between blood levels of environmental pollutants and liver cancer.
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2.4. Statistical Analysis
Conditional logistic regression was performed on matched pairs of cases and controls to 
calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for the 
association of BMI, diabetes, and serum glucose with risk of liver cancer [25]. To better 
describe the relationship between BMI and liver cancer, cubic splines were also utilized. All 
analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).
We examined effect measure modification of BMI by birth cohort (1884–1900, 1901–1924, 
1925–1944, and 1945–1962). Relative to other birth cohorts, the 1945–1965 birth cohorts 
have a unique risk factor profile for liver cancer, including high prevalence of HCV infection 
[26] and obesity [27]. We also examined effect modification by race (white, black, Asian, 
other), sex, diabetes (yes/no), cigarette smoking (never/ever), and alcohol consumption (not 
current or current drinker). Departures from the multiplicative null were assessed using 
likelihood ratio tests to compare regression models with and without a multiplicative term 
[25].
Potential confounders included cigarette smoking (never, former, current), alcohol 
consumption (not current or current drinker), and education (<high school, high school, 
some college or technical school, college graduate, or post-college graduate). If elimination 
of a variable changed the log odds ratio by ≥10%, the variable was considered a confounder 
and included in the model [25]; no covariates met this criterion. Thus, the final models 
accounted for only the matching terms.
Adjusted population attributable fractions (PAFs) for BMI and diabetes were computed 
utilizing a method for estimating PAFs from population-based case-controls studies with an 
adjusted odds ratios [28, 29].
2.5. Sensitivity Analyses
Models adjusted for both smoking and alcohol consumption were examined as a sensitivity 
analysis. As an additional sensitivity analysis, we examined the association between obesity 
and liver cancer prior to the beginning of the obesity epidemic. Thus, we restricted the 
analysis to individuals who entered during the first enrollment period in the MHC study 
(1964–1973).
3. RESULTS
Characteristics of cases and controls are shown in Table 1. Cases were slightly older and 
were more likely to be smokers and have lower educational attainment than the controls. 
Cases and controls were similar in the distribution of alcohol consumption and year of birth.
As shown in Table 2, obese individuals had a 2.4-fold increased risk of liver cancer 
(OR=2.38, 95% CI: 1.68–3.36), and overweight individuals had a 32% increased risk 
(OR=1.32, 95% CI: 1.03–1.70). A trend of 33% increased liver cancer risk per 5-kg/m2 was 
observed (OR=1.33, 95% CI: 1.15–1.53). When BMI was further stratified, severely obese 
individuals (BMI ≥40 kg/m2) had a nearly 5-fold increase in risk (OR=4.76, 95% CI: 1.48–
15.37). This increasing trend with increasing BMI was also seen in the spline model (Figure 
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1). Although non-significant, the associations of diabetes and serum glucose with liver 
cancer were suggestive of an increased risk (OR=1.28, 95% CI: 0.65–2.54 and OR=1.63, 
95% CI: 0.48–5.55, respectively). The population attributable fraction for obesity was 19.0% 
and for diabetes was 0.8%.
There was no evidence of effect measure modification by any covariate (p≥0.05) on the 
association between BMI and liver cancer in any of the models (Tables 3–5 and 
Supplemental Table 1). A trend of 17–36% increased liver cancer risk per 5-kg/m2 was 
observed in each birth cohort. When results were stratified by race/ethnicity, obese white 
individuals had a 2.8-fold increased risk of liver cancer (OR=2.76, 95% CI: 1.69–4.51), 
obese black individuals had a 2.3-fold increased risk (OR=2.29, 95% CI: 1.22–4.28), and 
obese Asians had a 2.5-fold increased risk (OR=2.50, 95% CI: 0.74–8.47). While there was 
no evidence of effect measure modification by sex, the point estimate for the association 
between obesity and liver cancer was somewhat higher in men (OR=2.68, 95% CI: 1.73–
4.16) then women (OR=2.00, 95% CI: 1.14–3.52). When we stratified by sex and race/
ethnicity, we observed a 3-fold increased risk of liver cancer among obese black males 
(OR=3.05, 95% CI: 1.28, 7.26). Among white and Asian males, obese individuals were also 
at an increased risk of liver cancer (OR=3.37, 95% CI: 1.82–6.24 and OR=2.26, 95% CI: 
0.57–8.95, respectively).
In the sensitivity analysis adjusted for smoking and drinking, the results were not 
substantially different than our main model (Supplemental Table 2). Similarly, when the 
study population was restricted to individuals who entered during the first enrollment period, 
results were robust for obesity (Supplemental Table 3).
4. DISCUSSION
This study examined the association between BMI, diabetes, and serum glucose and liver 
cancer. In this study, each 5-kg/m2 increase in BMI was associated with a 33% increased 
risk of liver cancer. Obese individuals were at a 2.4 fold increased risk of liver cancer, while 
overweight individuals were at a 32% increased risk. Diabetes and serum glucose were 
possibly associated with an increased risk of liver cancer.
Previous studies have reported that adiposity is associated with an increased risk of liver 
cancer. In a recent meta-analysis of prospective studies, overweight and obesity were 
associated with an 18% and 83% increased risk of liver cancer, respectively [10]. Another 
meta-analysis reported a 39% increased risk of liver cancer with each 5 kg/m2 increase [30]. 
Two recent studies from the US reported similar results to the prior meta-analyses [11]
(Campbell et al., Under Review). Our results are more similar to a SEER-Medicare analysis, 
which reported a 2.5-fold increased risk of liver cancer associated with diabetes or obesity 
[31].
The US Liver Cancer Pooling Project examined the category of BMI ≥40 kg/m2, but only 
reported a 2.5 fold increase in risk (Campbell et al., Under Review). In the current study, we 
report almost a 5-fold increase in risk of liver cancer. Additionally, the Liver Cancer Pooling 
Project (Campbell et al., Under Review) and the US Multiethnic Cohort Study [11] reported 
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differences in the association between obesity and liver cancer by race, specifically a lack of 
association between BMI and liver cancer among blacks. We did not find notable differences 
by race/ethnicity in our population. Conversely to what was reported by the Liver Cancer 
Pooling Project and Multiethnic Cohort Study and replicated in the Southern Communities 
Cohort Study, we found a 3-fold increased risk of liver cancer among obese black men. 
Differences between previous studies and our study could be due to prevalence of liver 
cancer risk factors, differing birth cohorts, or chance.
Disease incidence is affected by the changing prevalence of risk factors to which a 
population is exposed. If the prevalence of non-adipose liver cancer risk factors is high in a 
population (e.g., high prevalence rates of HBV or HCV infection), the “baseline” incidence 
proportion (i.e., the proportion of non-obese individuals being diagnosed with liver cancer) 
will be high and the proportion of cases associated with obesity will be relatively low. Thus, 
strength of effect, as measured by a ratio of proportions, depends on how common or rare 
other disease mechanisms are, in which obesity is not a factor [25]. Here, we hypothesize 
that the underlying prevalence of liver cancer risk factors, such as HBV/HCV infection, 
alcohol consumption, smoking, or other unknown risk factors, differs between these studies. 
This could cause the association between obesity and liver cancer among black males to be 
attenuated. In the Multiethnic Cohort/Southern Communities Cohort Study and Liver Cancer 
Pooling Project, the percentage of never-smokers among black males was slightly lower than 
the current report (31.8 and 30.8 vs. 35.5%), but the percentage of non-drinkers was higher 
(41.5 and 30.6 vs. 21.9%). Unfortunately, we lacked information on HBV and HCV in our 
cohort to investigate the differences in prevalence between the current study and previous 
studies.
In the current analysis, the strength of association between obesity and liver cancer among 
black males was attenuated when we included the 1945–1962 birth cohorts in the model 
(OR=3.05, 95% CI: 1.28–7.26) versus excluding these birth cohorts (OR=3.38, 95% CI: 
1.18–9.68). The 1945–1965 birth cohorts are known to have a high prevalence of HCV 
infection, and within these birth cohorts, the prevalence of HCV infections among blacks is 
nearly twice what is reported in whites [26]. Although HCV is currently the main risk factor 
for liver cancer among US blacks [31], HCV is unlikely to be the main risk factor in the 
future, as the highest-risk 1945–1965 birth cohorts age out of the population and new second 
generation direct-acting antivirals are increasingly utilized to treat HCV infections, which 
have higher sustained virologic response rate, fewer side effects, and require a shorter course 
of treatment. However, the rates of obesity are forecast to continue to increase. In 2012, 
more than a third (34.9%) of adults were categorized as obese, with the highest rate of 
47.8% among blacks (37.1% for black men and 56.6% for black women) [32]. By 2030, 
these rates are forecast to be between 39.5–50.7% [33]. Thus, obesity is likely to become an 
ever-more important risk factor for liver cancer among blacks, in addition to other groups.
The population attributable fraction is also affected by the prevalence of the exposure. In a 
recent study of SEER-Medicare, the population attributable fraction of diabetes and/or 
obesity was 36.6% [31]. In the current study, we report a population attributable fraction of 
19.0% for obesity and 0.8% for diabetes. The lower population attributable fractions in our 
study reflect the lower prevalence of obesity (8.3% among controls) and diabetes (2.8% 
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among controls) relative to the SEER-Medicare study (34.7% of controls with diabetes 
and/or obesity), since the KPNC MHC cohort was primarily enrolled before the obesity 
epidemic in the US. Thus, we expect that the current attributable fraction for obesity and 
diabetes and liver cancer is higher than shown here and will increase in the future.
Diabetes has been consistently associated with a 2–2.5 fold increased risk of liver cancer 
[12–15]. A similar association was found in the US Liver Cancer Pooling Project (Campbell 
et al., Under Review). Two studies which have examined serum glucose also report an 
increased risk of liver cancer [16, 17]. In the current study, we report a possible increased 
risk of liver cancer associated with diabetes and serum glucose. However, our sample size 
was limited to determine a precise estimate of risk. In addition, the prevalence of diabetes 
was low.
While this analysis included information on several major confounders (e.g., smoking and 
alcohol consumption), smoking and/or drinking information was unavailable for 
approximately 38% of study participants. However, when we adjusted for these covariates 
among participants with information on smoking and drinking, our results did not 
substantially differ (Supplemental Table 2). Additionally, this study did not include 
information on other important potential confounders, such as HBV and HCV infection 
status. However, we did stratify by birth cohort and conducted a sensitivity analysis 
excluding the 1945–1965 birth cohorts, for whom the prevalence of HCV differs from other 
birth cohorts (data not shown). Information on histologic subtype of liver cancer (e.g., 
hepatocellular carcinoma, intrahepatic cholangiocarcinoma, etc.) was not available. 
Additionally, we only have single exposure measurement at baseline for BMI, diabetes, and 
glucose, which does not account for the within person variability over time. We also did not 
have glucose measurements available on all participants – only individuals recruited between 
1974 and 1985 had these measurements available. Finally, we are limited in our 
interpretation of some estimates due to small sample size, especially for underweight 
participants and stratifications by birth cohort and race.
Strengths of this study include use of a racially and ethnically diverse population, with long-
term follow-up and a comprehensive cancer registry. The study population is more racially 
and ethnically diverse than the US population, which allowed examination of the obesity-
liver cancer association among minority groups. Additionally, BMI was measured during a 
standardized physical examination by trained examiners, using a systematic protocol and 
standardized instruments, and serum glucose was utilized as a biomarker of pre-diabetes and 
diabetes status in addition to self-reported diabetes status.
5. CONCLUSION
In summary, our finding of a positive association between obesity and liver cancer suggests 
that a higher BMI may increase the risk of liver cancer in the US. Further research is needed 
to elucidate the role of obesity and diabetes, specifically by race/ethnicity, sex, and birth 
cohort, in relation to liver cancer in the US.
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Figure 1. 
Cubic spline graph of the adjusted ORs (represented by the solid line) and 95% CIs 
(represented by the dotted lines) for the association between body mass index at enrollment 
(kg/m2) and risk of liver cancer (knots: 18.5, 25, 30; referent: 21.75).
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Table 1
Distribution of Characteristics Among Liver Cancer Cases and Controls.
Controls
(N=4,489)
Liver Cancer Cases
(N=450)
N (%) N (%)
Age at Enrollment (years), mean (sd) 41.6 (11.5) 44.4 (11.7)
Race
  White 2309 (53.8) 224 (53.9)
  Black 867 (20.2) 85 (20.4)
  Asian/Pacific Islander 715 (16.7) 76 (18.3)
  Other 404 (9.4) 31 (7.5)
  Missing 194 34
Sex
  Male 3027 (67.4) 303 (67.3)
  Female 1462 (32.6) 147 (32.7)
Education
  High School or less 473 (15.0) 63 (25.3)
  High School 951 (30.1) 74 (29.7)
  Some College/Vocational 607 (19.2) 58 (23.3)
  College Degree 559 (17.7) 32 (12.9)
  Graduate Degree 566 (17.9) 22 (8.8)
  Missing 1333 201
Alcohol
  Not Current Drinker 729 (24.2) 60 (25.0)
  Current 2277 (75.8) 180 (75.0)
  Missing 1483 210
Cigarette Smoking Status
  Non-Smoker 1272 (45.0) 88 (38.1)
  Former Smoker 547 (19.4) 33 (14.3)
  Current Smoker 1005 (35.6) 110 (47.6)
  Missing 1665 219
Birth Cohort
  1894–1900 79 (1.8) 10 (2.2)
  1901–1924 1720 (38.3) 173 (38.4)
  1925–1944 2014 (44.9) 197 (43.78)
  1945–1962 676 (15.1) 70 (15.6)
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Table 2
Adjusted* Odds Ratios (OR) and 95% Confidence Intervals (CI) for Associations Between Body Mass Index, 
Diabetes, and Serum Glucose at Enrollment and Risk of Liver Cancer.
No. Controls No. Liver
Cancer Cases
OR† (95% CI)
Body Mass Index, kg/m2
  <18.5 51 6 1.36 (0.57, 3.25)
  18.5–<25 1,721 155 1.00 Referent
  25–<30 1,217 139 1.32 (1.03, 1.70)
  ≥30 281 56 2.38 (1.68, 3.36)
Body Mass Index, per 5 kg/m2 3,270 356 1.33 (1.15, 1.53)
  p for trend <0.0001
Diabetes
  No 2,436 257 1.00 Referent
  Yes 76 10 1.28 (0.65, 2.54)
Serum Glucose, mg/dL
  <140 861 158 1.00 Referent
  140–199 43 12 1.39 (0.70, 2.76)
  ≥200 11 4 1.63 (0.48, 5.55)
Serum Glucose, per 10 mg/dL 915 174 1.00 (0.96, 1.05)
  p for trend 0.99
*Stratified by matching factor.
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